

Resignation of Non-Executive Director

PainChek Limited (ASX: PCK) (“PainChek” or “the Company”) advises that Mr Ross Harricks has notified the Board of his resignation as a Non-Executive Director of the Company, effective 1 September 2026.

Mr Harricks has served on the Board since 30 September 2016. During his tenure, PainChek progressed from the commercialisation of university research into a regulatory-cleared health technology business with operations and commercial activity across multiple international markets.

The Board thanks Mr Harricks for his contribution and service to PainChek over this period. Following the recent refresh of PainChek’s leadership team and Board, the Company remains focused on disciplined execution of its strategy and accelerating commercial growth across its key markets.

This announcement has been authorised for release by the Board of PainChek Limited.

ENDS

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

David Tasker
Chapter One Advisors
dtasker@chapteroneadvisors.com.au
+61 433 112 936

About PainChek

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

ASX ANNOUNCEMENT

2 September 2026



Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom and most recently FDA De Novo clearance in the United States.

PainChek® has contracts with over 2,000 aged care facilities, with more than 22,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is setting a new benchmark for pain assessment. Being the first TGA-approved and FDA-cleared medical device for pain assessment, PainChek® combines AI and Human Intelligence to detect pain in people who cannot reliably self-report.

For more information, visit: <https://painchek.com>